search
Back to results

Effects of Dietary Intervention and Surgery on NAFLD (Non-Alcoholic Fatty Liver Disease) (EDISON)

Primary Purpose

Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Bariatric Surgery Candidate

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Roux-en-Y Gastric Bypass (RYGB) surgery
Sleeve Gastrectomy (SG) surgery
Sponsored by
University of Oxford
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-Alcoholic Fatty Liver Disease focused on measuring non-alcoholic fatty liver disease, bariatric surgery

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Bariatric surgery is already planned for the participant
  • Participant is willing and able to give informed consent for participation in the study.
  • Aged ≥18 or ≤75 years.
  • Body Mass Index ≥35 ≤55 kg/m2

Exclusion Criteria:

  • Contraindication to MRI
  • Prior or current participation in a CTIMP that could affect study results
  • History of alcoholism or a greater than recommended weekly alcohol intake (14 units per week)
  • History of albumin allergy
  • Anticoagulant treatment
  • Pregnant or nursing mothers
  • Type 2 Diabetes
  • A liver disease other than NAFLD
  • Histological confirmation of lack of NAFLD on liver biopsy
  • Large hiatus hernia (that would prohibit Sleeve Gastrectomy)
  • Active gastrooesophageal reflux disease (that would prohibit Sleeve Gastrectomy)
  • Active malabsorptive intestinal disease (that would prohibit Roux-en-Y Gastric Bypass surgery)

Sites / Locations

  • University of Oxford

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Roux-en-Y Gastric Bypass (RYGB) surgery

Sleeve Gastrectomy (SG) surgery

Arm Description

Outcomes

Primary Outcome Measures

Change in liver fat content
Change in liver fat content as measured on MRI scan +/- fibroscan

Secondary Outcome Measures

Hepatic fatty acid synthesis
measured by incorporation of 2H2 palmitate from 2H2O into very low density lipoprotein triglyceride (VLDL-TG) and contribution of de novo lipogenesis and uptake and re-esterification to the hepatic triglyceride pool in liver biopsy
Changes in relative contributions of pathways involved in lipid homeostasis
measured using mathematical modelling of results from stable isotope mixed meal test
Changes in fasting and postprandial plasma lipid concentration
measured using a clinical analyser (in fasting states and in response to mixed meal test)
Changes in fasting and postprandial plasma glucose concentration
measured using a clinical analyser measured using a clinical analyser (in fasting state and in response to mixed meal test)
Change in the incorporation of 13C (from dietary fat) into CO2
measured using a breath analyser (in fasting state and in response to mixed meal test)
Expression changes (gene/protein) in adipose tissue biopsies
measured using techniques such as quantitative real-time PCR (polymerase chain reaction) and ELISA (enzyme- linked immunosorbent assay)
Change in fat mass
Proportional (% relative to baseline and lean mass) and absolute changes measured using DXA scan and bioimpedence analysis
Change in lean mass
Proportional (% relative to baseline and fat mass) and absolute changes measured using DXA scan and bioimpedence analysis
Change in functional strength
measured using hand dynamometer
changes in fasting and post-prandial peptides/proteins (e.g. PYY, GLP-1, insulin)
measured using ELISA (in fasting state and in response to mixed meal test)
change in weight
measured in kilograms using weighing scales
change in body mass index (BMI)
weight measured in kilograms using weighing scales and combined with height in metres to report BMI in kg/m^2
change in status of metabolic diseases (e.g. diabetes) / metabolic disease risk scores
measured with blood tests (e.g. hba1c), by recording clinical changes including medication requirements and clinical data (e.g. blood pressure)
complications, re-operation, mortality
clinical events will be recorded
changes in subcutaneous, visceral and pancreatic fat
measured on MRI scan

Full Information

First Posted
May 23, 2017
Last Updated
May 9, 2023
Sponsor
University of Oxford
search

1. Study Identification

Unique Protocol Identification Number
NCT03186859
Brief Title
Effects of Dietary Intervention and Surgery on NAFLD (Non-Alcoholic Fatty Liver Disease)
Acronym
EDISON
Official Title
Effects of Dietary Intervention and Surgery on NAFLD (Non-Alcoholic Fatty Liver Disease)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
June 9, 2017 (Actual)
Primary Completion Date
August 30, 2020 (Actual)
Study Completion Date
August 30, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Oxford

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Approximately 90% of people undergoing bariatric surgery have NAFLD, which is a condition where fat accumulates in the liver and can lead to inflammation and scarring. It mostly causes no symptoms, however, in the most advanced cases there is an increased risk of liver cancer or liver failure. NAFLD is currently managed by weight loss and treating associated diseases such as diabetes. No medicines have been licensed to directly treat it but bariatric surgery has been shown to be usually beneficial, although it is unknown whether some operations are better than others. It is also unclear whether this is due to general weight loss or other factors. This study will be conducted in a hospital setting and aims to determine what changes in liver fat and fat processing occur after pre-operative low calorie diet and the two most common types of bariatric surgery (Roux-en-Y Gastric Bypass and Sleeve Gastrectomy. Participants will have ten study visits, four of which may be combined with NHS appointments. Participants will undergo investigations including MRI scans to measure changes in NAFLD and DEXA scans to measure changes in fat and fat-free mass (FFM). Participants will also undergo mixed meal testing to which stable isotopes (deuterated water and 13c-palmitate) will be added to allow changes in fat processing to be detected. In addition to samples taken as part of NHS care, blood, urine, liver and fat (visceral and subcutaneous (abdominal and gluteal)) will be used for research. Visits will take place before and after low calorie diet and bariatric surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Bariatric Surgery Candidate, Obesity, Morbid
Keywords
non-alcoholic fatty liver disease, bariatric surgery

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
41 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Roux-en-Y Gastric Bypass (RYGB) surgery
Arm Type
Active Comparator
Arm Title
Sleeve Gastrectomy (SG) surgery
Arm Type
Active Comparator
Intervention Type
Procedure
Intervention Name(s)
Roux-en-Y Gastric Bypass (RYGB) surgery
Intervention Description
RYGB operation using surgeons' standard technique
Intervention Type
Procedure
Intervention Name(s)
Sleeve Gastrectomy (SG) surgery
Intervention Description
SG surgery using surgeons' standard technique
Primary Outcome Measure Information:
Title
Change in liver fat content
Description
Change in liver fat content as measured on MRI scan +/- fibroscan
Time Frame
Baseline measurement just prior to initiation of routine preoperative low calorie diet (this starts 3-4 weeks before surgery) compared to measurements on completion of this (within a week of surgery) and at 20% weight loss and 1 year after SG or RYGB
Secondary Outcome Measure Information:
Title
Hepatic fatty acid synthesis
Description
measured by incorporation of 2H2 palmitate from 2H2O into very low density lipoprotein triglyceride (VLDL-TG) and contribution of de novo lipogenesis and uptake and re-esterification to the hepatic triglyceride pool in liver biopsy
Time Frame
liver biopsy taken during SG or RYGB
Title
Changes in relative contributions of pathways involved in lipid homeostasis
Description
measured using mathematical modelling of results from stable isotope mixed meal test
Time Frame
Baseline measurement just prior to initiation of routine preoperative low calorie diet (this starts 3-4 weeks before surgery) compared to measurements on completion of this (within a week of surgery) and at 20% weight loss and 1 year after SG or RYGB
Title
Changes in fasting and postprandial plasma lipid concentration
Description
measured using a clinical analyser (in fasting states and in response to mixed meal test)
Time Frame
Baseline measurements just prior to initiation of routine preoperative low calorie diet (this starts 3-4 weeks before surgery) compared to measurements on completion of this (within a week of surgery) and at 20% weight loss and 1 year after SG or RYGB
Title
Changes in fasting and postprandial plasma glucose concentration
Description
measured using a clinical analyser measured using a clinical analyser (in fasting state and in response to mixed meal test)
Time Frame
Baseline measurement just prior to initiation of routine preoperative low calorie diet (this starts 3-4 weeks before surgery) compared to measurements on completion of this (within a week of surgery) and at 20% weight loss and 1 year after SG or RYGB
Title
Change in the incorporation of 13C (from dietary fat) into CO2
Description
measured using a breath analyser (in fasting state and in response to mixed meal test)
Time Frame
Baseline measurement just prior to initiation of routine preoperative low calorie diet (this starts 3-4 weeks before surgery) compared to measurements on completion of this (within a week of surgery) and at 20% weight loss and 1 year after SG or RYGB
Title
Expression changes (gene/protein) in adipose tissue biopsies
Description
measured using techniques such as quantitative real-time PCR (polymerase chain reaction) and ELISA (enzyme- linked immunosorbent assay)
Time Frame
Baseline measurement just prior to initiation of routine preoperative low calorie diet (this starts 3-4 weeks before surgery) compared to measurements on completion of this (within a week of surgery) and at 20% weight loss and 1 year after SG or RYGB
Title
Change in fat mass
Description
Proportional (% relative to baseline and lean mass) and absolute changes measured using DXA scan and bioimpedence analysis
Time Frame
Baseline measurement just prior to initiation of routine preoperative low calorie diet (this starts 3-4 weeks before surgery) compared to measurements on completion of this (within a week of surgery) and at 20% weight loss and 1 year after SG or RYGB
Title
Change in lean mass
Description
Proportional (% relative to baseline and fat mass) and absolute changes measured using DXA scan and bioimpedence analysis
Time Frame
Baseline measurement just prior to initiation of routine preoperative low calorie diet (this starts 3-4 weeks before surgery) compared to measurements on completion of this (within a week of surgery) and at 20% weight loss and 1 year after SG or RYGB
Title
Change in functional strength
Description
measured using hand dynamometer
Time Frame
Baseline measurement just prior to initiation of routine preoperative low calorie diet (this starts 3-4 weeks before surgery) compared to measurements on completion of this (within a week of surgery) and at 20% weight loss and 1 year after SG or RYGB
Title
changes in fasting and post-prandial peptides/proteins (e.g. PYY, GLP-1, insulin)
Description
measured using ELISA (in fasting state and in response to mixed meal test)
Time Frame
Baseline measurement just prior to initiation of routine preoperative low calorie diet (this starts 3-4 weeks before surgery) compared to measurements on completion of this (within a week of surgery) and at 20% weight loss and 1 year after SG or RYGB
Title
change in weight
Description
measured in kilograms using weighing scales
Time Frame
Baseline measurement just prior to initiation of routine preoperative low calorie diet (this starts 3-4 weeks before surgery) compared to measurements on completion of this (within a week of surgery) and at 20% weight loss and 1 year after SG or RYGB
Title
change in body mass index (BMI)
Description
weight measured in kilograms using weighing scales and combined with height in metres to report BMI in kg/m^2
Time Frame
Baseline measurement just prior to initiation of routine preoperative low calorie diet (this starts 3-4 weeks before surgery) compared to measurements on completion of this (within a week of surgery) and at 20% weight loss and 1 year after SG or RYGB
Title
change in status of metabolic diseases (e.g. diabetes) / metabolic disease risk scores
Description
measured with blood tests (e.g. hba1c), by recording clinical changes including medication requirements and clinical data (e.g. blood pressure)
Time Frame
Baseline measurement just prior to initiation of routine preoperative low calorie diet (this starts 3-4 weeks before surgery) compared to measurements on completion of this (within a week of surgery) and at 20% weight loss and 1 year after SG or RYGB
Title
complications, re-operation, mortality
Description
clinical events will be recorded
Time Frame
Baseline measurement just prior to initiation of routine preoperative low calorie diet (this starts 3-4 weeks before surgery) compared to measurements on completion of this (within a week of surgery) and at 20% weight loss and 1 year after SG or RYGB
Title
changes in subcutaneous, visceral and pancreatic fat
Description
measured on MRI scan
Time Frame
Baseline measurement just prior to initiation of routine preoperative low calorie diet (this starts 3-4 weeks before surgery) compared to measurements on completion of this (within a week of surgery) and at 20% weight loss and 1 year after SG or RYGB

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Bariatric surgery is already planned for the participant Participant is willing and able to give informed consent for participation in the study. Aged ≥18 or ≤75 years. Body Mass Index ≥35 ≤55 kg/m2 Exclusion Criteria: Contraindication to MRI Prior or current participation in a CTIMP that could affect study results History of alcoholism or a greater than recommended weekly alcohol intake (14 units per week) History of albumin allergy Anticoagulant treatment Pregnant or nursing mothers Type 2 Diabetes A liver disease other than NAFLD Histological confirmation of lack of NAFLD on liver biopsy Large hiatus hernia (that would prohibit Sleeve Gastrectomy) Active gastrooesophageal reflux disease (that would prohibit Sleeve Gastrectomy) Active malabsorptive intestinal disease (that would prohibit Roux-en-Y Gastric Bypass surgery)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeremy Tomlinson, MD PhD
Organizational Affiliation
University of Oxford
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Oxford
City
Oxford
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effects of Dietary Intervention and Surgery on NAFLD (Non-Alcoholic Fatty Liver Disease)

We'll reach out to this number within 24 hrs